Back

Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis.

31 August 2024 (15:00 - 15:50)
Organised by: Logo
Congress Presentation Part of: Obesity, weight loss, and cardiovascular disease Metabolic Syndrome, Insulin, Insulin Resistance ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Lorenzo Martin Lobo

Education Administration - Argentine Army, Buenos Aires (Argentina)

8 More presentations in this session

Presentation thumbnail
Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on mitochondrial-derived peptide-c and on markers of neurohumoral activation
Doctor I. Ikonomidis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Effects of SGLT-2i and GLP-1RA in vascular function parameters: the impact of the weight loss
Doctor E. Bletsa (Zurich, CH) Doctor P. Stampouloglou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Association of obesity and metabolic health status with cerebral small vessel disease in stroke-free individuals
Associate Professor A. ishida (Okinawa, JP)
Abstract Slides Video
Presentation thumbnail
Parallel improvement of arterial stiffness with weight loss following intensification of antidiabetic treatment
Doctor E. Bletsa (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Sex-biased proteomic regulation in obesity
Doctor H. Halland (Bergen, NO)
Abstract Slides Video

Access the full session

Session thumbnail
Obesity, weight loss, and cardiovascular disease

The Event

Event poster

ESC Congress 2024

31 August 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Proportion of patients with systemic inflammation and their characteristics for groups at high cardiovascular risk in phase 3 randomized placebo-controlled trials of semaglutide (SELECT, SOUL, FLOW)
thumbnail
Congress Presentation
Inflammation in obesity-related HFpEF: the STEP-HFpEF programme
thumbnail
Congress Presentation
GLP-1 RA as first-line therapy to improve outcomes?

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources